3/4/2013

A link between osteoporosis treatments containing calcitonin salmon and cancer risk is possible, according to briefing documents from FDA staff reviewers. The reviewers raised questions about the drugs' usefulness in preventing bone breaks due to osteoporosis in postmenopausal women, the reviewers said. An FDA panel is set to discuss the products on Tuesday.

Full Story:
Reuters

Related Summaries